Once a week, every week, the health center at Stamford High School offers sophomore Roger Sanchez an oasis—someplace he can talk to a trusted adult about life’s pressures and problems, a place he feels free and unjudged. School work, sports commitments, family and social obligations: life as a teenager can be stressful, he says. If it weren’t for the health center, conveniently located where he spends most of his days, he would have a much harder time accessing counseling sessions that help him cope with anxiety. “The health center helps me out academically, emotionally and physically,” he said, and he recommends it to friends. “They get nervous, kind of, but I try my best to get them to come in.
The rate of infants dying suddenly and unexpectedly has dropped in recent years, but data show that racial disparities persist. Babies born to American Indian and Alaska Natives and African American families suffer much higher rates of sudden unexpected infant deaths (SUID) than other races and ethnicities, data from the Centers for Disease Control and Prevention (CDC) show. Between 2011 and 2014, 194.1 American Indian and Alaska Native infants and 170.2 African American infants per 100,000 live births died from SUID nationwide. Those rates are significantly higher compared with 83.8 for whites, 51.1 for Hispanics and 32.1 for Asian or Pacific Islander babies per 100,000 live births, during the same time period. SUID encompasses sudden infant death syndrome, commonly known as SIDS, as well accidental suffocation and strangulation in bed, and other unspecified causes of death in children up to a year old.
Edith Baker of Plainville faced a devastating reality that patients with advanced cancer inevitably confront. She had stopped responding to conventional treatment. Radiation and chemotherapy could no longer contain her stage 4 bladder cancer. But there was a ray of hope. Baker’s oncologist at Saint Francis Hospital and Medical Center referred her to a clinical trial at UConn Health involving two immunotherapy drugs: the FDA-approved Keytruda (pembrolizumab) from Merck & Co., credited with successfully treating former President Jimmy Carter’s melanoma; and Epacadostat (IDO1 inhibitor), an experimental drug from Incyte Corp.
If you’re 65 and living in Connecticut, you can expect – on average – roughly 16 more years of good health, according to a new federal study. In fact, the state ranks number seven for healthy seniors, says another study, this one from the United Health Foundation. That’s if you’re white. If you’re African American, your healthy life expectancy drops to 12 years, or age 77. And from other studies, Hispanics and Latinos don’t fare much better.